Cybin Inc. - CYBN STOCK NEWS

Cybin Inc. (AMEX:CYBN) has filed an international patent application under the Patent Cooperation Treaty (PCT) for innovative methods of delivering psychedelic medications through inhalation. The application aims to secure patent coverage across 153 countries, enhancing the Company's intellectual property portfolio. This approach may optimize session timing, reduce drug dosages while maintaining efficacy, and provide better control during sessions. The filing is part of Cybin's ongoing development program for its proprietary psychedelic molecule, CYB004.

Cybin Inc. announces milestones achieved by its subsidiary, Adelia Therapeutics Inc., under a December 2020 contribution agreement. Adelia has met certain Year 2 Q1 milestones, leading to the issuance of $706,586.69 in Class B shares to Adelia shareholders. These shares can be exchanged for Cybin common shares at a 10 to 1 ratio starting December 2021, with phased exchange limits until December 2023. The firm focuses on advancing psychedelic therapies, aiming to enhance dosing efficacy and address unmet medical needs.

Cybin Inc. announced key management changes and engagement with ROK Consulting to enhance market communications. Dr. Amir Inamdar joined as Chief Medical Officer for European Operations, and Dr. Geoff Varty became Head of Research & Development. Lori Challenger was promoted to Chief Compliance, Ethics & Administrative Officer, while Robert Mino was named General Counsel. The engagement with ROK includes a three-month contract at $500,000 per month, plus options for shares at CDN$2.78. This aims to improve the company's engagement with financial markets.

Cybin, a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present at two investor conferences on September 30, 2021. The conferences are the Cantor Virtual Global Healthcare Conference at 2:00 PM ET and the Benzinga Healthcare Small Cap Conference at 12:15 PM ET, followed by a panel discussion on mental health therapies. Both events will be available via live webcast. Cybin is dedicated to advancing psychedelic drug development for psychiatric disorders, employing innovative drug discovery and delivery techniques.

Cybin, a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The presentation will be available on-demand starting at 7:00 AM ET and can be accessed for 90 days via the provided link. As a leader in psychedelic therapeutics, Cybin employs innovative drug discovery platforms and treatment regimens aimed at psychiatric disorders. However, all forward-looking statements are subject to risks and uncertainties.

Cybin Inc. (NYSE AMERICAN:CYBN) announced that its subsidiary, Adelia Therapeutics, has met certain milestones for Year 1 Q3 as per a December 4, 2020 agreement. In recognition, 9,392.6 Class B shares will be issued to Adelia shareholders, valued at approximately $317,471.09. These shares can be exchanged for Cybin common shares at a ratio of 10 to 1, subject to specific timing restrictions. Cybin focuses on psychedelic therapies for psychiatric disorders, leveraging innovative drug discovery and delivery methods.

Cybin (NEO:CYBN, AMERICAN:CYBN), a biotechnology company, has filed two international patent applications under the Patent Cooperation Treaty (PCT), potentially covering 153 countries. These applications pertain to a library of phenethylamine compounds and novel psychedelic compounds identified through research. The patents aim to strengthen the CYB005 program addressing therapy-resistant psychiatric disorders. Cybin’s drug development focuses on novel drug discovery, efficient delivery systems, and treatment regimens targeting mental health needs, including major depressive disorder and alcohol use disorder.

Cybin Inc. (NEO:CYBN) announced the filing of a new non-provisional patent application following a favorable international search report for its May 2021 PCT application. The International Patent Searching authority has validated claims within the filing, which supports the company’s pre-clinical and research programs. Cybin's portfolio now includes 14 patent filings, over 50 proprietary molecules, and 4 active drug programs targeting mental health disorders. CEO Doug Drysdale emphasized the ongoing development of the company's IP portfolio to enhance new discoveries in psychedelic therapeutics.

Cybin has announced the election of Theresa Firestone to its board of directors during a shareholder meeting on August 16, 2021. A total of 45,681,073 common shares were represented, accounting for 30.77% of total shares. Key voting results include the appointment of Zeifmans LLP as auditor with 99.76% approval, setting the board size at six directors with 99.87% approval, and amendments to the equity incentive plan with 95.43% support. Additionally, a shareholder rights plan was approved to protect shareholders during potential takeover bids.